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Erk1/2Trefoil factor 1 (TFF1), a member of the trefoil peptide family, is not only associatedwithmucosal protection and
restoration but is also correlatedwith tumorigenesis of the gastrointestinal tract. In an early study, we performed
sequence analysis and identiﬁed one potential miR423-5p binding site within the 3′-untranslated region of TFF1
usingmicroRNA target prediction tools. In the current study,we demonstrated that the codingDNA regionwithin
TFF1 is also a candidate for miR218-5p targeting. We used real-time PCR and in situ hybridization to analyze the
correlation betweenmiR218-5p and TFF1 expression in tumor lesions and paracancerous tissue in gastric cancer
(GC) samples. Additionally, endogenous and exogenous TFF1 were suppressed by miR218-5p in gastric cancer
cells and inﬂuenced the progression of GC in an Erk1/2-dependent manner. Targeting miR218-5p may provide
a novel strategy for the treatment of GC.
© 2015 Elsevier B.V. All rights reserved.Summary
Our study demonstrated that miR218-5p targets TFF1 in an Erk1/2-
dependent manner, and regulates the proliferation of human GC cells.
Targeting miR218-5p may provide a novel strategy for the treatment
of GC.
1. Introduction
Stomach cancer is the second leading cause of cancer death world-
wide [1]. It is typically asymptomatic in the early stage, which is a
clear challenge for prevention. Sustaining proliferative ability is a signif-
icant hallmark of cancer [2]. The trefoil factor family, comprising TFF1,
TFF2 and TFF3, is characterized by having at least one copy of the trefoilroRNA; GC, gastric cancer; Erk,
uence; 3′-UTR, 3′-untranslated
nterology, Zhongshan Hospital
Xiamen 361004, Fujian, China.
86 592 2212328.
jianl@xmu.edu.cn (J.-L. Ren).motif, a 40-amino acid domain that contains three conserved disulﬁdes
[3]. Because the gastrointestinal track is themain position of TFF synthe-
sis inmammals, TFF1, which is secreted by gastric surface foveolar cells,
is normally highly expressed in the human stomach to maintain gastric
epithelial structure and function [4]. Similar to TFF1, TFF2 is expressed
in the stomach, whereas TFF3 is almost exclusively found in the intes-
tines and colon. However, this speciﬁc distribution is disturbed when
disease occurs [5]. In metastatic gastric cancer, TFF1 is up-regulated
compared with the primary cancer [6]. After gastric cancer resection,
serum TFF1 levels could be a biomarker of recurrence [7]. TFF1 displays
a close relationship with gastric cancer.
MicroRNAs are approximately 22-nucleotide-long small, non-coding
RNAs that regulate gene expression by targeting mRNAs for cleavage or
transcriptional repression at the transcriptional, translational or post-
translational level [8]. Recent evidence has suggested that microRNA
might also act as both a tumor suppressor and an oncogene [9]. As a
novel potential biomarker for gastric cancer detection,miR218-5p regu-
lates growth, invasion and metastasis during cancer progression by
targetingdifferent genes [10–12]. Additionally,miR218-5pplays diverse
roles in the tumor progression of other cancers, such as oral, nasopha-
ryngeal, lung and cervical cancer [13–16].
According to a computer-based set of predictions, targeted se-
quences within the TFF gene cluster demonstrate multiplicity of the
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ing DNA sequence [17]. Our previous study demonstrated that miR423-
5p regulates proliferation and invasion ability of gastric cancer cells by
targeting TFF1 [18]. Here, we demonstrated that the coding region
within TFF1 is also a candidate for miR218-5p targeting.
2. Methods
2.1. Ethics statement
This study was approved by the Ethics Committee of Zhongshan
Hospital, which is afﬁliated with Xiamen University (Xiamen, Fujian
Province, China) (No. 20081009). Written consent was obtained from
all participants. All procedures involving experimental animals were
performed in accordance with protocols approved by the Committee
for Animal Research of Xiamen University and complied with the
Guide for the Care and Use of Laboratory Animals (NIH publication No.
86-23, revised in 1985).
2.2. Cell culture
The BGC-823 and SCG-7901 cell lines were purchased from Cell
Bank, Shanghai Institutes for Biological Sciences (Cell Bank, CAS,
Shanghai, China). Both cell lines were cultured in RPMI 1640 medium
(Life Technologies, USA) supplemented with 10% fetal bovine serum
(Life Technologies) and 1% penicillin G/streptomycin (Life Technolo-
gies). All cell lines were incubated at 37 °C in an atmosphere of 95%
air and 5% CO2.
2.3. Cell transfection
HiPerFect Transfection Reagent and Attractene Transfection Reagent
were purchased from QIAGEN and used for transfection and co-
transfection. Cells were seeded in 24-well or 96-well plates with
25 nM miR218-5p mimic or 100 nM miR218-5p inhibitor (QIAGEN)
and transfected according to the manufacturer's instructions. Cells
were incubated for 24 h post-transfection for microRNA, mRNA and
protein analysis, cell proliferation assays and ELISA.
2.4. Establishment of stable TFF1 overexpressing cells
cDNAs encoding human TFF1were obtained from theGES-1 cell line
(gastric mucosal epithelium cells). The forward primer sequence was
5′-AGAGAATTCGGATCCATGGCCACCATGGAGA-3′, and the reverse
primer sequence was 5′-CTTCCATGGCTCGAGAAATTCACACTC-3′.
The human TFF1 overexpression vector was constructed based on
pcDNA6.0. BGC-823 and SGC-7901 cells. Cells stably overexpressing
TFF1 were established by selection with blasticidin (100 μg/mL;
InvivoGen; Cat. #ant-bl) for 4 weeks. BGC-823 and SGC-7901 cells
that were stably transfected with the empty pcDNA6.0 vector were
used as controls. The mRNA and protein expression levels of TFF1
were measured using RT-PCR and Western blot analysis, respectively.
2.5. Measurement of RNA expression
Total RNA, including miRNA, was extracted from human gastric
cancer cells or tissues using a miRNeasy Micro Kit (QIAGEN; Cat. No.
217004) according to the manufacturer's instructions. First-strand
cDNA synthesis and RT-PCR assays of miRNA were performed using
the miScript II RT Kit (QIAGEN; Cat. No. 218260) and miScript SYBR
Green PCR Kit (QIAGEN; Cat. No. 218073), respectively, according to
the manufacturer's instructions. The RT-PCR primers of miR218-5p
were purchased from QIAGEN. Real-time quantiﬁcation of TFF1 mRNA
expression was performed using the following primers: forward, 5′-
CCAGTGTGCAAATAAGGGCTGC-3′, and reverse, 5′-AGGCAGATCCCTGC
AGAAGTGT-3′.2.6. In situ hybridization
In situ hybridization was performed on 5-μm parafﬁn serial sections
to investigate the clinical and biological relevance of miR218-5p in GC
development using the miRCURY LNA™ microRNA ISH Optimization
Kit (FFPE) (#90010; Exiqon, United States). Digoxin-labeled hsa-
miR218-5p probe (miRCURY LNA™ Detection probe; 250 pmol; 5′-
DIG and 3′-DIG labeled; Exiqon, United States)was used at a concentra-
tion of 1.5 pM to detect miR218-5p staining. The slides were heated at
95 °C for 8 min to denature the samples, placed on ice immediately,
and then subjected to hybridization at 55 °C overnight. The next day,
the slides were washed in SSC buffer (pH 7.0; S1030; Solarbio, Beijing,
China), and then the microRNA ISH Buffer and Controls Kit (90010;
Exiqon, United States) protocol was followed.
Next, 3% H2O2 was used to block endogenous peroxidase for
10min at room temperature, followed by incubation with the prima-
ry antibody McAb anti-DIG IgG (#305359; Invitrogen) for 30 min at
room temperature. After washing with PBS, the sections were incu-
bated with goat anti-mouse IgG antibody (#651671A; Invitrogen).
Staining patterns were independently examined by two reviewers.
After incubation with 0.04% 3,3′-diaminobenzidine (DAB) and
0.05% H2O2 for 20 min, the sections were stained with DAB and
counterstained with hematoxylin.
2.7. Immunohistochemical staining
Each tissue section was deparafﬁnized, rehydrated and then rinsed
with PBS. High-pressure antigen retrieval was carried out in citrate
antigen retrieval solution (MVS-0101; Maixin Biotech, Fuzhou, China).
Endogenous peroxidase was blocked using endogenous peroxidase
blocking solution (SP KIT-A1; Maixin Biotech, Fuzhou, China). The
sections were incubated with 1% Triton X-100 for 10 min, followed by
10% normal donkey serum for 15 min at room temperature. Next, the
sections were incubated overnight with rabbit anti-human TFF1 poly-
clonal antibody (ab92377; Abcam) diluted by 1:250 in IHC Antibody
Diluent (ABD-0030; Maixin Biotech, Fuzhou, China) at 4 °C.
The next day, the sections were rinsed with PBS, incubated with
biotin-labeled secondary antibody for 20 min at room temperature,
rinsed againwith PBS, and incubatedwith horseradish peroxidase poly-
mer conjugate (Elivision™ Super HRP (Mouse/Rabbit) IHC Kit-9922;
Maixin Biotech, Fuzhou, China). The sections were stained with the
chromogen 3,3-diaminobenzidine from the DAB Detection Kit (DAB-
0031; Maixin Biotech, Fuzhou, China) for approximately 3 min and
counterstained with hematoxylin.
2.8. Western blot analysis
Total proteinwas extracted from cells and tissues using theMamma-
lian Cell Lysis Reagent (Thermo Scientiﬁc, Rockford, IL, USA) according
to the manufacturer's protocol. Protein concentrations were deter-
mined using the Bradford Protein Assay Kit (Thermo Fisher Scientiﬁc,
Lafayette, CO, USA) as recommended by the manufacturer. Equal
amounts of total protein were separated by 10% SDS-PAGE and then
transferred to polyvinylidene ﬂuoride (PVDF) membranes.
Themembranes were blockedwith 5% bovine serum albumin (BSA)
at room temperature for 40 min and then incubated with the appropri-
ate primary antibodies overnight at 4 °C. The membranes were subse-
quently incubated with HRP-conjugated secondary antibodies for 1 h,
and the protein bands were detected using an ECL Western Blotting
Detection Kit (Santa Cruz Biotechnology, Santa Cruz, CA, USA). Primary
antibodies against TFF1 were purchased from Santa Cruz Biotechnology
(Santa Cruz, CA, USA), and Erk1/2 and p-Erk1/2 were purchased from
Cell Signaling Technology (Boston, MA, USA). Primary antibodies
against GAPDH, tubulin antibody, as well as horseradish peroxidase-
conjugated anti-rabbit and anti-mouse secondary antibodies, were
obtained from Sigma-Aldrich (St. Louis, MO, USA).
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site mutagenesis
SGC7901 cells were seeded in 24-well plates at a density of
6 × 104 per well immediately prior to transfection. The pmirGLO
dual-luciferase miRNA target expression vector was purchased
from Promega (Cat. E1330). The total length of TFF1-CDS segments
or the mutations of the miR218-5p binding site in the TFF1-CDS frag-
ment were inserted into a luciferase reporter gene (Supplementary
Fig. 1). The miR218-5p mimic or inhibitor was co-transfected with
the vectors into SGC7901 cells. Forty-eight hours post-transfection,
the cells were assayed for both ﬁreﬂy and Renilla luciferase using
the dual-luciferase reporter assay (Promega; E1910).
2.10. CCK-8 cell proliferation assay
Cells transfectedmiR218-5pmimic or inhibitor for 24 hwere seeded
into 96-well plates at a density of 8 × 103 cells/well. After 24, 48, 72 or
96 h, 10 μL of Cell Counting Kit-8 solution (DoJinDo, Tokyo, Japan) was
added into each well, and the cells were incubated for 1 h. The absor-
bance was measured using a microplate reader at 450 nm.
2.11. Enzyme-linked immunosorbent assay (ELISA)
After miR218-5p mimic or inhibitor administration for 48 h, the
supernatants of cells were tested using the TFF1 ELISA kit (USCN LifeFig. 1.miR218-5p expression is negatively correlated with TFF1 expression in gastric cancer. (A
sion of miR218-5p in GC patient tissues (P=0.01). (C) GC samples were examined by hematox
(ISH). (a) HE staining showed normal, adjacent and tumor tissue. (b) IHC indicated that yellowi
tissue. However, in tumor tissue, TFF1 was scarcely expressed. (c) ISH staining indicated that m
TFF1 was highly expressed, and relatively high expression was observed in the tissue in whichScience, Houston, TX, USA) according to the manufacturer's instruc-
tions. Detection reagents A and B were added followed by the substrate
solution, and the reactionwas terminatedwith the STOP solution. Final-
ly, the absorbance at 450 nm was measured using a microplate reader.2.12. Construction of lentivirus-based miR218-5p-overexpressing cells
The recombinant lentivirus supernatants of miR218-5p and the
corresponding controls were purchased from GenePharma Co., Ltd.
(Shanghai, China). The titers of the lentiviral stocks were ≤1 × 108
(TU)/mL. TFF1-overexpressing BGC-823 and SGC-7901 cells were
seeded in 6-well plates at a density of 8 × 105 cells/well. A volume of
100 μL of lentivirus supernatant was dripped into each well transfected
by Polybrene (GenePharma, Shanghai, China). Stable miR218-5p over-
expression was conﬁrmed using RT-PCR analysis.2.13. Colony formation assay
Brieﬂy, cells were seeded in 6-well plates at a density of 500 cells
per well and incubated for 7 days. After staining the cells with crystal
violet, the numbers of cell colonies containing at least 50 cells were
counted. Lentivirus-based miR218-5p-overexpressing cells and
their corresponding controls were subjected to the colony formation
assay.) Relative expression of TFF1 in GC patient tissues (P=0.000). (B) Corresponding expres-
ylin-eosin (HE) and immunohistochemistry (IHC) staining, as well as in situ hybridization
sh-brown TFF1 granuleswere highly expressed in normal tissue and expressed in adjacent
iR218-5p (brown granules) was expressed at relatively low levels in the tissue in which
there was almost no TFF1 expression.
Fig. 2.miR218-5p binds to the CDS of TFF1. (A) Schematic model of the predictive binding site of miR218-5p targeting the CDS of TFF1. The positions of the miR218-5p targeting sites in
TFF1-CDS indicated sequence alignment ofmiR218-5p and TFF1 CDS. (B) TFF1 is a direct target of miR218-5p. SGC7901 cells were co-transfectedwith luciferase reporter plasmid contain-
ing eitherwild-type (pmirGLO-TFF1) or mutant (pmirGLO-Mut) TFF1 CDS, and the luciferase activity of wild-type TFF1 CDS was dramatically decreased compared withmutant TFF1 CDS
and the negative control when the miR218-5p mimic was introduced (*P b 0.05). The Renilla luciferase activity of each sample was normalized by ﬁreﬂy luciferase activity. The data are
shown as the mean ± standard deviation of three independent experiments.
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Four-week-old nude mice purchased from the Laboratory Animal
Center (Shanghai, China) were maintained in a speciﬁc pathogen-
free environment. Next, 5 × 106 lentivirus-based miR218-5p-
overexpressing and corresponding control cells were subcutaneous-
ly injected into the nude mice. After 5 days, solid tumors were
observed in all of the mice that received cell injections. The size of
the xenograft was monitored and recorded once every 3 days for
20 days using a Vernier caliper. The tumor volume was calculated
as follows: [length (mm) × width (mm)2] / 2.
3. Results
3.1. miR218-5p negatively expresses with TFF1 in gastric cancer
To determine the relationship between miR218-5p and the TFF1
gene, we analyzed the mRNA expression of miR218-5p and TFF1 in 42
pairs of GC patient tumor lesions and paracancerous tissue samples.
TFF1 expression levels were lower in the tumor tissues than the normal
controls (Fig. 1A; P value = 0.000), whereas the relative expression ofFig. 3.miR218-5p directly downregulates TFF1 expression and secretion and regulates theprolif
ly transfected into BGC-823 and SGC-7901 cells (left). miR218-5p mimic downregulated TFF1 i
cretion of TFF1 according to ELISA (*P b 0.05). (C) A CCK-8 assay indicated that the proliferati
compared with that in cells transfected with the control (*P b 0.05). (D) Chemically synthes
(left). miR218-5p inhibitor upregulated TFF1 in BGC-823 and SGC-7901 cells (right) (*P b 0.05
5p inhibitor increased TFF1 secretion. (*P b 0.05). (F) A CCK-8 assay showed that the proliferatio
compared with the control (*P b 0.05). (G) Protein expression levels of TFF1 with miR218-5p mmiR218-5p was opposite with the expression of TFF1 at the mRNA
level (Fig. 1A and B; P= 0.01).
FourGC sampleswere examined for TFF1 expression using immuno-
histochemistry staining (Fig. 1C, IHC-TFF1). Yellowish-brown TFF1
granules were observed primarily in the cytoplasm. TFF1 was highly
expressed in normal tissue and expressed in adjacent tissue. However,
in tumor tissue, TFF1 was scarcely expressed. Next, we performed in
situ hybridization to verify miR218-5p expression (Fig. 1C, ISH-
miR218-5p). miR218-5p (brown granules) was expressed at relatively
low levels in the tissue in which TFF1was highly expressed. In contrast,
miR218-5p was expressed at relatively highly levels in the tissue in
which TFF1 was scarcely expressed. Thus, a negative correlation
between the expression ofmiR218-5p and TFF1 was observed in gastric
cancer.
3.2. TFF1 is a target gene of miR218-5p
Using microRNA target prediction tools, we performed sequence
analysis and identiﬁed one potential miR218-5p binding site within
the TFF1 coding region (Fig. 2A). We constructed two luciferase
reporters, one containing a wild-type TFF1 coding DNA sequenceeration of gastric cancer cells. (A) Chemically synthesizedmiR218-5pmimicwas transient-
n BGC-823 and SGC-7901 cells (right) (*P b 0.05). (B) miR218-5p mimic inhibited the se-
on of cells transiently transfected with the miR218-5p mimic was signiﬁcantly increased
ized miR218-5p inhibitor was transiently transfected into BGC-823 and SGC-7901 cells
). (E) An ELISA of the supernatant of BGC-823 and SGC-7901 cells showed that miR218-
n of cells transiently transfectedwith themiR218-5p inhibitor was signiﬁcantly decreased
imic or inhibitor treatment.
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975Y. Shi et al. / Biochimica et Biophysica Acta 1852 (2015) 970–979containing the miR218-5p binding site (pmirGLO-TFF1) and another
containing a mutated TFF1 CDS (pmirGLO-Mut). We then performed
luciferase reporter assays to verify a direct interaction betweenFig. 4.miR218-5p counteracts the growth inhibition caused by TFF1. (A) and (B) Stable TFF1-o
the protein (A) and mRNA levels (B; *P b 0.05). (C) miR218-5p mimic downregulated TFF1 exp
(right) compared with the control. (D) miR218-5p mimic suppressed TFF1 secretion in TFF1-
following transfection of miR218-5p mimic in TFF1-overexpressing BGC-823 (left) and SGC-79
miR218-5p reversed the inhibition of colony formation in TFF1-overexpressing cells (left). Nu
(right, *P b 0.05).miR218-5p and the CDS of TFF1 (Fig. 2B). The luciferase reporter
constructs were transfected into SGC7901 cells along with miR218-5p
mimic oligonucleotides. Compared with the control, the relativeverexpressing BGC-823 and SGC-7901 cells were generated. TFF1 was highly expressed at
ression in TFF1-overexpressing cells at both the mRNA (left, *P b 0.05) and protein levels
overexpressing cells compared with control (*P b 0.05). (E) Analysis of cell proliferation
01 (right) cells and control cells using a CCK-8 assay (*P b 0.05). (F) Stable expression of
mbers of valid colonies (≥50 cells) in TFF1-overexpressing cells treated with miR218-5p
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pressed to 83% expressionwith treatmentwith 5 nMmimic and 51% ex-
pressionwith treatmentwith 25 nMmimic. However, the activity of the
reporter construct mutated at the speciﬁc miR218-5p target site was
unaffected by simultaneous transfection with the miR218-5p mimic.
Thus, we conclude that TFF1 was a target gene of miR218-5p and that
miRNA218-5p negatively regulated TFF1 expression by binding to its
CDS.
3.3. miR218-5p down-regulates TFF1 expression and secretion and
regulates the proliferation of human gastric cancer cells
To demonstrate the silencing effects of miR218-5p on TFF1, we per-
formed transient transfection in GC cells using chemically synthesized
mimic or inhibitor for miR218-5p. Compared with the control group,
miR218-5p overexpression (Fig. 3A, left) remarkably reduced TFF1
expression at the mRNA level (Fig. 3A, right). As shown in Fig. 3A,
TFF1 mRNA was decreased by 50% in BGC-823 cells and by 56% in
SGC-7901 cells after treatment with 25 nM of miR218-5pmimic. Corre-
spondingly, the concentration of TFF1 secreted into the cells superna-
tant was decreased to 75% expression in BGC-823 cells and 56%
expression in SGC-7901 cells, as detected by ELISA (Fig. 3B). Additional-
ly, a CCK-8 assay was performed for cell viability. As shown in Fig. 3C,
the proliferation of cells with miR218-5p up-regulation was signiﬁcant-
ly enhanced compared with that in control cells.
We also transiently transfected the chemically synthesized inhibitor
of miR218-5p. Compared with the control group, transfection of BGC-Fig. 5. Lentivirus-based miR218-5p expression counteracts TFF1 expression. (A) Overexpress
miR218-5p expression in TFF1-overexpressing BGC-823 and SGC-7901 cells (left, *P b 0.05). L
*P b 0.05). (B) Isolated xenograft tumors from the two nude mouse groups (n = 6). (C) In vi
BGC-823 (upper) and SGC-7901 (lower) cell xenografts (n = 6, *P b 0.05, **P b 0.01). (D) W
(n= 6, *P b 0.05).823 and SGC-7901 cells with the inhibitor caused remarkable inhibition
of miR218-5p expression and resulted in increased TFF1 mRNA expres-
sion. As shown in Fig. 3D, TFF1 mRNAwas up-regulated by 1.5-fold and
1.7-fold, respectively, following the inhibition of miR218-5p after treat-
ment with 100 nM of the inhibitor. Moreover, consistent with the
induction of TFF1mRNA levels by themiR218-5p inhibitor, TFF1 protein
secretion was signiﬁcantly increased by 1.2-fold and 1.3-fold in the
BGC-823 and SGC-7901 cells, respectively, as indicated by ELISA
(Fig. 3E). As shown in Fig. 3F, the proliferation of cells transiently
transfected with the miR218-5p inhibitor was signiﬁcantly suppressed
compared with that of the corresponding control. We also performed
Western blotting to analyze the expression of TFF1 with miR218-5p
mimic or inhibitor treatment at the protein level (Fig. 3G).
These results suggested that miR218-5p suppressed the expression
and secretion of TFF1 and regulated the proliferation of gastric cancer
cells.
3.4. miR218-5p reverses the growth inhibition caused by TFF1 in vitro
Considering miR218-5p binding to the CDS of the TFF1 gene, TFF1-
overexpressing cell lines were generated in BGC-823 and SGC-7901
cells (Fig. 4A and B). The miR218-5p mimic was transfected 24 h later,
and TFF1 expression and secretion were downregulated (Fig. 4C and
D, respectively). Next, a CCK-8 assaywas performed to evaluate cell pro-
liferation. As shown in Fig. 4E, the proliferation of TFF1-overexpressing
cells transfected with the miR218-5p mimics was signiﬁcantly in-
creased compared with that of cells transfected with correspondingion of miR218-5p mediated by the lentivirus system. RT-PCR analysis of lentivirus-based
entivirus-based miR218-5p inhibited TFF1 expression in TFF1-overexpressing cells (right,
vo tumor growth resulting from the lentivirus-based miR218-5p in TFF1-overexpressing
estern blot (upper) and RT-PCR (lower) analysis of TFF1 expression in xenograft tumors
Fig. 6.Western blot analysis indicating that miR218-5p negatively regulates TFF1 in a MEK/Erk1/2-dependent manner. (A) and (B) Protein expression of total Erk1/2 and phosphor-Erk1/2 in wild-type BGC-823 and SGC-7901 cells treated with
miR218-5p mimic or inhibitor and corresponding controls for 24 h (*P b 0.05). (C) and (D) Protein expression of total MEK and Erk1/2, phosphor-MEK, and phosphor-Erk1/2 in TFF1-overexpressing BGC-823 and SGC-7901 cells treated with
miR218-5pmimic or negative control for 24 h (*P b 0.05). (E) and (F) Phosphorylation of MEK and Erk1/2 in the xenograft tumor tissues induced by the miR218-5p- or negative control-treated cells with TFF1 overexpression in an in vivo transplan-











978 Y. Shi et al. / Biochimica et Biophysica Acta 1852 (2015) 970–979controls. Additionally, we performed colony formation assays to further
characterize the effect of miR218-5p in TFF1-overexpressing cells. The
number of colonies (more than 50 cells) from gastric cancer cells
transfected with the miR218-5p mimics was 1.36-fold and 1.25-fold
higher than that of the control group in TFF1-overexpressed BGC-823
and SGC-7901 cells, respectively (Fig. 4F). Thus, the cell growth inhibi-
tion caused by TFF1 overexpression was recovered with miR218-5p
treatment.
3.5. miR218-5p negatively regulates TFF1 in vivo
For continuous expression, a lentivirus-based miR218-5p overex-
pression system was generated in TFF1-overexpressing BGC-823 and
SGC-7901 cells (Fig. 5A). To determine whether miR218-5p could sup-
press TFF1 during gastric cancer development in vivo, lentivirus-based
miR218-5por corresponding control cellswere subcutaneously injected
into nude mice. miR218-5p overexpression signiﬁcantly promoted
xenograft tumor growth compared with the control groups (Fig. 5B
and C, n= 6, *P b 0.05, **P b 0.01). On 20 days after injection, the exper-
imental mice were euthanized. Inhibition of miR218-5p for TFF1 was
maintained at the end of the study period as analyzed by Western
blotting and RT-PCR (Fig. 5D).
3.6. miR218-5p negatively regulates TFF1 in an Erk1/2-dependent manner
To clarify the signaling pathways involved in the miR218-5p-
mediated regulation of gastric cancer cell growth, we analyzed the
protein expressions of total MEK and phosphor-MEK, as well as down-
stream proteins of total Erk1/2 and phosphor-Erk1/2 in wild-type
(Fig. 6A and B) and TFF1-overexpressing BGC-823 and SGC-7901 cells
(Fig. 6C and D) treated with miR218-5p or negative control for 24 h.
Our data showed that the phosphorylation levels of MEK and Erk1/2
were upregulated in the miR218-5p-treated group compared with the
negative control.Fig. 7. Inhibition of Erk1/2 suppressed miR218-5p-induced proliferation in GC cells. (A) Wild-t
were performed after BGC-823 (left) or SGC-7901 (right) cells were incubated with or without
pressing BGC-823 (left) or SGC-7901 (right) cells were incubated with and without U0126 (1
independently three times.We further analyzed the phosphorylation of MEK and Erk1/2 in
the xenograft tumor tissues induced by the miR218-5p- or negative
control-treated cells with TFF1 overexpression in an in vivo trans-
plantation model. TFF1 was present at higher levels in the TFF1-
over-expressing cells. Consistent with the in vitro results, the
phosphorylation levels of MEK and Erk1/2 were downregulated in
the miR218-5p-treated BGC-823 (Fig. 6E) and SGC-7901 (Fig. 6F)
xenografts compared with that of the negative control.
To conﬁrmwhether the inhibition of Erk1/2 suppresses themiR218-
5p-induced proliferation in GC cells, we applied the Erk inhibitor of
U0126 to block the Erk1/2 signaling pathway as follows. Wild-type
BGC-823 (Fig. 7A, left) and SGC-7901 (Fig. 7A, right) cells and stable
TFF1-overexpressing BGC-823 (Fig. 7B, left) and SGC-7901 (Fig. 7B,
right) cells were incubated with or without U0126 (10 μM) for 24 h,
48 h and 72 h (P b 0.05). DMSO was employed as the control. Then, a
CCK-8 assay was performed to assess cell proliferation. Our results
demonstrated that the U0126 treatment groups signiﬁcantly sup-
pressed GC cell proliferation compared with the controls (P b 0.05).
Thus, miR218-5p regulates cancer cell growth via a MAPK/MEK/Erk1/
2-mediated signaling pathway.
4. Discussion
Our previous research suggests that TFF1 may play a role in gastric
mucosa protection and epithelial restitution [19]. Trefoil peptides are
also used to protect against mucosal injury by oral administration or
other approaches [20,21]. Additionally, increased TFF1 expression in
peritumoral tissue suggests that TFF1 is associated with themechanism
of carcinoma suppression and differentiation. TFF1 is involved in the
inhibition of tumor invasion and migration and could be a target for
enhancing sensitivity to chemotherapy by being involved in apoptosis
resistance [22].
Downregulation of TFF1 expression during gastric neoplastic trans-
formation is associated with activation of the NF-κB pathway throughype GC cells were incubated with and without the Erk inhibitor. CCK-8 proliferation assay
U0126 (10 μM) for 24, 48 and 72 h (DMSO as control; *P b 0.05). (B) Stable TFF1-overex-
0 μM) for 24, 48 and 72 h (DMSO as control; *P b 0.05). All experiments were performed
979Y. Shi et al. / Biochimica et Biophysica Acta 1852 (2015) 970–979IL-1β or TNF-α [23]. TFF1 is a secretory protein that can be affected by
many infectors, including microRNA. In the present study, miR218-5p
negatively regulates TFF1 in an Erk1/2-dependent manner both
in vitro and in vivo. miR218-5p not only inhibited the expression of
TFF1 but also reduced its secretion in supernatants from cancer cells.
Because TFF1 was secreted by the mammalian gastrointestinal tract
[7], we detected the supernatant after the miR218-5p mimic was
transfected into gastric cancer cells 48 h later. The concentration of
TFF1 in the supernatant was also reduced compared with that in the
control group. Additionally, transfecting the miR218-5p inhibitor
produces the opposite effect.
MicroRNAs are approximately 22-nucleotide-long RNAs that
negatively regulate mRNAs primarily via binding to the 3′-untranslated
region. Additionally, microRNAs can also function as regulons targeting
mRNAs by binding the coding DNA sequences of target genes [24]. In
our present study, luciferase reporter assays and subsequent mutagen-
esis of coding sequences of the TFF1 gene revealed the interaction of
miR218-5p with the target gene TFF1. This result was consistent with
the computer-based set of predictions.
MicroRNAs inﬂuence transcription, translation and post-translation
of target genes. One microRNA can interact with many genes, and one
target gene can be regulated by numerous microRNAs. We previously
demonstrated that miR423-5p regulates the proliferation and invasion
ability of gastric cancer cells by targeting the 3′-UTR of TFF1 and induces
the expression of cyclin D1, cyclin D3 and β-catenin [18]. We co-
transfected the miR218-5p mimic or inhibitor with or without
miR423-5p into BGC-823 or SGC-7901 cells. TFF1 expressionwas signif-
icantly decreased compared with transfection of miR218-5p alone after
co-transfection (Supplementary Fig. 1A). Furthermore, cell proliferation
was signiﬁcantly increased after co-transfection of miR218-5p and
miR423-5p in BGC-823 (Supplementary Fig. 1B) and SGC-7901
(Supplementary Fig. 1C) cells. These results suggested that miR423-5p
may cooperate with miR218-5p to regulate gastric cancer progression
by targeting the TFF1 gene.
Supplementary data to this article can be found online at http://dx.
doi.org/10.1016/j.bbadis.2015.01.016.
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